Articles On Imugene (ASX:IMU)

World Overnight SPI Overnight 7055.00 – 13.00 – 0.18% S&P ASX 200 7030.30 – 7.90 – 0.11% S&P500 4274.51 + 0.98 0.02% Nasdaq Comp 13092.85 + 29.24 0.22% DJIA 33550.27 – 68.61 – 0.20% S&P500 VIX 18.22 – 0.72 – 3.80%...

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

The S&P/ASX 200 Index (ASX: XJO) is out of form on Tuesday. In afternoon trade, the benchmark index is down 0.5% to 7,043.1 points. Four ASX shares that are not letting that hold them back are listed below. Here's why they are pushing...

It hasn't been a great day for the S&P/ASX 200 Index (ASX: XJO) and most ASX shares so far this Tuesday. At the time of writing, the ASX 200 has slipped by 0.71%. But that hasn't stopped one ASX exchange-traded fund (ETF) from hitting...

Another day, another set of 52-week highs for ASX uranium shares! Most uranium miners are rising on Tuesday, in contrast to the rest of the market. The S&P/ASX 200 Energy Index (ASX: XEJ) started the day higher but is now down 0.19%...

It's been a pretty awful start to this Tuesday's trading for the S&P/ASX 300 Index (ASX: XKO) and ASX 300 shares so far today. At present, the ASX 300 has slipped by 0.32% and is back to around 7,000 points. So given this slip for the...

The S&P/ASX 200 Index (ASX: XJO) has delighted investors hoping for a reprieve from the share market today with a green session. After falling every single trading day last week, the ASX...

The S&P/ASX 200 Index (ASX: XJO) is out of form on Monday. In afternoon trade, the benchmark index is down 0.2% to 7,057 points. Four ASX shares that are not letting that hold them back are listed below. Here's why they are rising:...

Cancer fighter Imugene has positioned itself as one of the most cashed-up med-techs on the ASX after raising a further $18.2 million from a share placement plan (SPP) to add to a previous $35 million placement.

The TechnologyOne Ltd (ASX: TNE) share price is starting the week strongly. At the time of writing, the ASX 200 tech share is up 2.5% to $15.65. This compares favourably to the performance of the ASX 200 index, which is down 0.35%. Why is...

Clinical stage immuno-oncology company Imugene (ASX: IMU) has raised $18.2 million from a share purchase plan component of a capital raising exercise to fund the acquisition of worldwide licensing rights for lead candidate azer-cel to targe...

World Overnight SPI Overnight 7186.00 – 14.00 – 0.19% S&P ASX 200 7196.60 – 33.80 – 0.47% S&P500 4443.95 – 9.58 – 0.22% Nasdaq Comp 13678.19 – 32.05 – 0.23% DJIA 34517.73 – 106.57 – 0.31% S&P500 VIX 14.11 + 0.11 0....

According to the World Health Organisation (WHO), cancer is the leading cause of death globally. WHO defines cancer as a generic term for a large group of diseases that can affect any part of the body with malignant tumours and neoplasms. W...

The ASX 200 benchmark falls 0.5% as central bank boogeymen spook investors Energy pretty much on its own out front of the rest of the sectors Small caps led by lithium and new metal minnows with some sturdy new finds   Local markets hav...

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

The S&P/ASX 200 Index (ASX: XJO) had another shaky day on Tuesday. Yesterday seemed to show that investors couldn't decide what they wanted out of the markets, with stints on both positive and ne...

Clinical-stage immuno-oncology company Imugene has secured new Japan Patent Office protection for its “PD1-Vaxx” that is currently in the development stage of a bid to target non-small cell lung cancer.

Clinical stage immuno-oncology company Imugene (ASX: IMU) has been granted a new patent by the Japanese Patent Office for its PD1-Vaxx clinical candidate. The grant protects the immunotherapeutic drug, which is a first-in-class programmed d...

Highlights Imugene’s first-in-class programmed death-1 (PD1) vaccine, PD1-Vaxx has been granted a Japanese patent. The patent extends protection to the matter composition and treatment method in cancer. Imugene Limited (ASX: IMU) h...

Imugene Limited (ASX: IMU) stock is in great demand with investors on Tuesday. In morning trade, the beaten-down biotech share is up almost 7% to 6.3 cents. Why is Imugene stock rising? Investors have been buying the biotech's shares after...

Clinical-stage immuno-oncology company Imugene (ASX:IMU) has announced the grant of a new patent for its PD1-Vaxx clinical drug candidate.

Futures point to the ASX opening modestly higher, bolstered by gains on Wall Street overnight. Overnight, Tesla shares surged 10 per cent in a vote of confidence for artificial intelligence, boosting the Nasdaq. Back home, here are so...

Cancer-fighter Imugene has received positive feedback from the US Food and Drug Administration on its proposed trials and commercial manufacture of “Azer-cel” to treat patients with certain blood cancers.

Cancer-fighter Imugene has received positive feedback from the US Food and Drug Administration on its proposed trials and commercial manufacture of “Azer-cel” to treat patients with certain blood cancers.

Lumos granted approvals by the US FDA for the ViraDx test Imugene receives positive feedback from FDA for CAR T cell therapy Genetic Technology expands its geneType Multi-Risk Test in Australia   Lumos granted US FDA approval for ViraDx M...

Imugene (ASX: IMU) has announced positive feedback from the US Food and Drug Administration (FDA) on a manufacturing process for lead candidate azer-cel (azercabtagene zapreleucel or allogeneic CD19 CAR T) for the treatment of patients with...

ASX futures were predicting the ASX will open slightly in the green to start the week in pre-morning trades, up 4 points. This comes on the back of a mostly green US Friday close as investors shift their focus to incoming US inflation da...

It ended up being a pretty lousy Tuesday for the S&P/ASX 200 Index (ASX: XJO) on the markets today. After yesterday’s positive start to the trading week, the ASX 200 took a backwards step during today...

Imugene (IMU) announces the clearance of the first cohort in its phase one MAST trial The trial is evaluating the safety of its novel cancer-killing virus, VAXINIA) As a result, Imugene is now recruiting its second cohort to test each...

Imugene has revealed that the phase-one trial of its anti-cancer virus “Vaxinia”, which is administered directly into the tumour, has passed the first cohort of its study, clearing the way for a second phase.

Sydney-headquartered clinical stage immuno-oncology specialist Imugene (ASX: IMU) continues to build momentum both scientifically and corporately with a number of new developments. On the science side, Imugene has made further strong progre...

It’s that time of the year again when S&P Dow Jones Indices announces the rebalance of the S&P/ASX Indices. According to the release, there will be a total of five companies entering the S&P/ASX 200 Index (ASX: XJO) at the n...

Futures indicate the ASX200 will open slightly higher as a new trading week commences, driven by growing confidence that the US Federal Reserve will pause at its next rates meeting due to the increase in unemployment in the country. In A...

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

Clinical stage immuno-oncology specialist Imugene (ASX: IMU) has added another key appointment to its growing team of specialists. Dr John Byon has been named as senior vice president of clinical development, bringing a wealth of experience...

The S&P/ASX 200 Index (ASX: XJO) has recorded yet another gain today, albeit one not quite on the same levels as yesterday. Still, the ASX 200 has now risen every day this week so far, with today makin...

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

We’ve just had another mighty fine day for the S&P/ASX 200 Index (ASX: XJO) this Wednesday. After rising enthusiastically over both Monday and Tuesday, buying really stepped on the gas today. By the clo...

At the start of each week, I like to look at ASIC’s short position report to find out which shares are being targeted by short sellers. This is because I believe it is well worth keeping a close eye on short interest levels as high lev...

Neuren’s US FDA approval for trofinetide has seen its share price boosted ~130% in past year   Eye disease specialist Opthea is undertaking two Phase 3 trials to treat Wet AMD with results due in mid 2024 Anteris Technologies is developing...

With so many shares to choose from on the ASX, it can be difficult to decide which ones to buy. The good news is that brokers across the country are doing a lot of the hard work for you. Three top ASX shares that leading brokers have named...

Fresh from a strongly supported $35 million placement, ASX-listed immuno-oncology medtech Imugene is on a steadfast mission to activate the immune system of cancer patients to help treat and eradicate tumours.

Telstra Group Ltd (ASX: TLS) shares and Vanguard Australian Shares High Yield ETF (ASX: VHY) are both known for paying dividend income to investors. In this article, I’m going to look at which one could be the better choice for passive i...

By Greg Peel Choosing to Follow On It was a rock’n’roll session on the ASX200 on Friday, ahead of a flat close. The futures had said down -28 on Wall Street weakness, the ASX200 fell -22 points on the open, but by 12.30pm was up 21. Then it...

The pre-eminent benchmark of the Australian share market, the S&P/ASX 200 Index (ASX: XJO), narrowly avoided its third consecutive negative session on Friday. Today’s feeble finish to the week coincides with a financial milestone for C...

The ASX200 had a stronger session than expected, closing up, but only just. The real estate sector led the way gaining 1.8 per cent, utilities were also up by a per cent and materials just short of a per cent. In the green Goodman...

ASX 200 benchmark falls, gains and wanes its way to just 0.03% for the day. Real Estate, resources and gold (oh my!) lead a troubled bourse from disaster. Mining tech minnow Orexplore’s $1.55m BHP deal delivers a +150% gift for investors....

It has been another busy week for Australia’s top brokers. This has led to the release of a large number of broker notes. Three broker buy ratings that you might want to know more about are summarised below. Here’s why brokers think th...

The S&P/ASX 200 Index (ASX: XJO) is on course to record a small gain on Friday. In afternoon trade, the benchmark index is up 0.1% to 7,154.3 points. Four ASX shares that have failed to follow the market higher today are listed below...

The ASX200 has gone against expectations and lifted ever so slightly by 0.1 of a per cent mid-session. Real estate led gainers – up nearly 1.5 per cent – but the heat was on communications and consumer discretionary which have both shed...